These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 19719454)

  • 1. Current perspectives in prostate cancer vaccines.
    Arlen PM; Gulley JL
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1052-7. PubMed ID: 19719454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising novel immunotherapies and combinations for prostate cancer.
    Arlen PM; Mohebtash M; Madan RA; Gulley JL
    Future Oncol; 2009 Mar; 5(2):187-96. PubMed ID: 19284377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer vaccines: current directions and perspectives in prostate cancer.
    Mohebtash M; Gulley JL; Madan RA; Ferrara T; Arlen PM
    Curr Opin Mol Ther; 2009 Feb; 11(1):31-6. PubMed ID: 19169957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic prostate cancer vaccines: a review of the latest developments.
    Mohebtash M; Madan RA; Gulley JL; Arlen PM
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1296-301. PubMed ID: 19037836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer vaccines: the long road to clinical application.
    Baxevanis CN; Papamichail M; Perez SA
    Cancer Immunol Immunother; 2015 Apr; 64(4):401-8. PubMed ID: 25690791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development of immunotherapy for prostate cancer.
    Noguchi M; Koga N; Igawa T; Itoh K
    Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.
    Patel A; Fong L
    Oncology (Williston Park); 2018 Mar; 32(3):112-20. PubMed ID: 29548065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA vaccines for the treatment of prostate cancer.
    Alam S; McNeel DG
    Expert Rev Vaccines; 2010 Jul; 9(7):731-45. PubMed ID: 20624047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current immunotherapeutic strategies in prostate cancer.
    Grosso JF; Drake CG
    Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer vaccines in clinical trials.
    Lubaroff DM
    Expert Rev Vaccines; 2012 Jul; 11(7):857-68. PubMed ID: 22913261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic vaccines for prevention of prostate cancer.
    Naz RK; Shiley B
    Front Biosci (Schol Ed); 2012 Jan; 4(3):932-40. PubMed ID: 22202100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine therapy for prostate cancer.
    Sonpavde G; Spencer DM; Slawin KM
    Urol Oncol; 2007; 25(6):451-9. PubMed ID: 18047951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic vaccines for prostate cancer.
    Cha E; Fong L
    Curr Opin Mol Ther; 2010 Feb; 12(1):77-85. PubMed ID: 20140819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic vaccines for prostate cancer.
    Tarassoff CP; Arlen PM; Gulley JL
    Oncologist; 2006 May; 11(5):451-62. PubMed ID: 16720845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer: Better VISTAs ahead? Potential and pitfalls of immunotherapy.
    Madan RA; Gulley JL
    Nat Rev Urol; 2017 Aug; 14(8):455-456. PubMed ID: 28534538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review.
    Janiczek M; Szylberg Ł; Kasperska A; Kowalewski A; Parol M; Antosik P; Radecka B; Marszałek A
    J Immunol Res; 2017; 2017():4861570. PubMed ID: 29109964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for Prostate Cancer: Where We Are Headed.
    Schepisi G; Farolfi A; Conteduca V; Martignano F; De Lisi D; Ravaglia G; Rossi L; Menna C; Bellia SR; Barone D; Gunelli R; De Giorgi U
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29206214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in and prospects of immunotherapy for prostate cancer.
    Liu D; Wang L; Guo Y
    Cancer Lett; 2024 Oct; 601():217155. PubMed ID: 39127338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.